NASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis $39.75 +0.87 (+2.24%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$38.00▼$39.9850-Day Range$34.98▼$43.6052-Week Range$19.83▼$73.80Volume1.19 million shsAverage Volume1.49 million shsMarket Capitalization$4.82 billionP/E RatioN/ADividend YieldN/APrice Target$74.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Apellis Pharmaceuticals alerts: Email Address Apellis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside88.1% Upside$74.75 Price TargetShort InterestBearish12.50% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.48Based on 20 Articles This WeekInsider TradingSelling Shares$4.79 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.07) to $0.65 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.38 out of 5 starsMedical Sector138th out of 936 stocksPharmaceutical Preparations Industry55th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apellis Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.50% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 2.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 3.0 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Apellis Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest10 people have searched for APLS on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows6 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,793,591.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apellis Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.07) to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -11.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -11.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 24.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apellis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Apellis Pharmaceuticals Stock (NASDAQ:APLS)Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More APLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLS Stock News HeadlinesJuly 25 at 10:43 PM | msn.com3 Best Stocks to Buy Now, 7/24/2024, According to Top AnalystsJuly 25 at 5:12 AM | americanbankingnews.comApellis Pharmaceuticals (APLS) Set to Announce Quarterly Earnings on ThursdayJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 25 at 1:11 AM | americanbankingnews.comRobert W. Baird Reiterates Outperform Rating for Apellis Pharmaceuticals (NASDAQ:APLS)July 24 at 2:52 AM | markets.businessinsider.comApellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor’s Clinical FailureJuly 24 at 2:35 AM | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 23 at 4:17 AM | markets.businessinsider.comBuy Rating Affirmed on Apellis Pharmaceuticals Amid Promising Pegcetacoplan Trials and Expert OptimismJuly 22, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 20, 2024 | americanbankingnews.comQ2 2026 Earnings Forecast for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Issued By Zacks ResearchJuly 20, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 3.8% After Analyst DowngradeJuly 19, 2024 | americanbankingnews.comThe Goldman Sachs Group Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $77.00July 18, 2024 | prnewswire.comKuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law FirmJuly 18, 2024 | prnewswire.comKuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law FirmJuly 18, 2024 | globenewswire.comApellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial ResultsJuly 18, 2024 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Significant Growth in Short InterestJuly 18, 2024 | americanbankingnews.comQ1 2026 EPS Estimates for Apellis Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:APLS)July 9, 2024 | globenewswire.comApellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific MeetingSee More Headlines Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees770Year Founded2009Price Target and Rating Average Stock Price Target$74.75 High Stock Price Target$106.00 Low Stock Price Target$46.00 Potential Upside/Downside+88.1%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-528,630,000.00 Net Margins-79.67% Pretax Margin-79.24% Return on Equity-160.77% Return on Assets-49.79% Debt Debt-to-Equity Ratio0.35 Current Ratio3.77 Quick Ratio3.02 Sales & Book Value Annual Sales$396.59 million Price / Sales12.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book24.24Miscellaneous Outstanding Shares121,370,000Free Float113,113,000Market Cap$4.82 billion OptionableOptionable Beta0.88 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Cedric Francois M.D. (Age 52)Ph.D., Co-Founder, President, CEO & Director Comp: $1.44MMr. Mark Jeffrey Delong (Age 47)Chief Business & Strategy Officer Dr. Philip Ferrone M.D.Chief Medical Retina AdvisorKey CompetitorsEidos TherapeuticsNASDAQ:EIDXRa PharmaceuticalsNASDAQ:RARXOmerosNASDAQ:OMERRigel PharmaceuticalsNASDAQ:RIGLSeres TherapeuticsNASDAQ:MCRBView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 22,273 shares on 7/26/2024Ownership: 0.284%Allspring Global Investments Holdings LLCSold 42,985 shares on 7/26/2024Ownership: 0.060%Nisa Investment Advisors LLCSold 50,100 shares on 7/20/2024Ownership: 0.014%China Universal Asset Management Co. Ltd.Sold 8,922 shares on 7/20/2024Ownership: 0.012%Assenagon Asset Management S.A.Sold 1,288,906 shares on 7/18/2024Ownership: 0.605%View All Insider TransactionsView All Institutional Transactions APLS Stock Analysis - Frequently Asked Questions How have APLS shares performed this year? Apellis Pharmaceuticals' stock was trading at $59.86 on January 1st, 2024. Since then, APLS stock has decreased by 33.6% and is now trading at $39.75. View the best growth stocks for 2024 here. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The firm's quarterly revenue was up 284.3% on a year-over-year basis. What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Apellis Pharmaceuticals: Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and others. When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.61%), Bank of New York Mellon Corp (0.28%), Simplicity Wealth LLC (0.06%) and Allspring Global Investments Holdings LLC (0.06%). Insiders that own company stock include Pascal Deschatelets, Alec Machiels, Cedric Francois, A Sinclair Dunlop, David O Watson, Federico Grossi, Timothy Eugene Sullivan, Adam J Townsend, Jeffrey Eisele, Lukas Scheibler, Nur Nicholson, Mark Jeffrey Delong, Karen Lewis, James George Chopas, Caroline Baumal, Victoria L Brown and Morningside Venture Investment. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA) and Amarin (AMRN). This page (NASDAQ:APLS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
